Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,803 recalls · Class II, newest first

Class II · Moderate risk

Carisoprodol Tablets

Presence of Foreign Substance; metal particulates were visually observed in the tablets.

Terminated Particulate / foreign matter Watson Laboratories Inc NDC 0591-5513-05 D-397-2014
Class II · Moderate risk

Hydralazine HCL Tablets

Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.

Terminated Impurity / degradation Teva Pharmaceuticals USA NDC 00182-0555-89 D-1075-2014
Class II · Moderate risk

Hydralazine HCL Tablets

Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.

Terminated Impurity / degradation Teva Pharmaceuticals USA NDC 00182-0554-89 D-1074-2014
Class II · Moderate risk

Pyridostigmine Bromide Tablets USP

Failed Dissolution Specification: Corepharma Inc. is recalling Pyridostigmine Bromide Tablets USP 60 mg due to an out of specification dissolution test generated at the 30 month stability time point.

Terminated Dissolution failure Corepharma LLC NDC 64720-128-10 D-1079-2014
Class II · Moderate risk

Vitamin B-12 injections

Lack of Assurance of Sterility: The firm expanded the recall to other injectable products due to lack of assurance of sterility from poor aseptic practices observed at the firm.

Terminated Sterility / contamination Zions RX Formulations Services LLC dba RX Formuations Serv. D-1219-2014
Class II · Moderate risk

Bupivacaine 3%

Lack of Assurance of Sterility: The firm expanded the recall to other injectable products due to lack of assurance of sterility from poor aseptic practices observed at the firm.

Terminated Sterility / contamination Zions RX Formulations Services LLC dba RX Formuations Serv. D-1218-2014
Class II · Moderate risk

Sodium Bicarbonate 8.4%

Lack of Assurance of Sterility: The firm expanded the recall to other injectable products due to lack of assurance of sterility from poor aseptic practices observed at the firm.

Terminated Sterility / contamination Zions RX Formulations Services LLC dba RX Formuations Serv. D-1217-2014
Class II · Moderate risk

Potassium Phosphates 4.4mEq/3mM/mL Vials

Lack of Assurance of Sterility: The firm expanded the recall to other injectable products due to lack of assurance of sterility from poor aseptic practices observed at the firm.

Terminated Sterility / contamination Zions RX Formulations Services LLC dba RX Formuations Serv. D-1215-2014
Class II · Moderate risk

Propofol Injectible Emulsion

Presence of Particulate Matter: Glass defect located on the interior neck of the vial identified glass surface abrasions and visible embedded particulate matter which could result in the potential for small glass flakes or embedded metal particulate to become dislodged into the solution.

Terminated Particulate / foreign matter Hospira Inc. NDC 0409-4699-30 D-1033-2014
Class II · Moderate risk

HydrOXYzine HCI Tablets USP 50 mg

Good Manufacturing Practices Deviations: The product has an Active Pharmaceutical Ingredient from an unapproved source.

Terminated Unapproved drug KVK-Tech, Inc. D-1032-2014
Class II · Moderate risk

HydrOXYzine HCI Tablets USP 25 mg

Good Manufacturing Practices Deviations: The product has an Active Pharmaceutical Ingredient from an unapproved source.

Terminated Unapproved drug KVK-Tech, Inc. D-1031-2014
Class II · Moderate risk

HydrOXYzine HCI Tablets USP 10 mg

Good Manufacturing Practices Deviations: The product has an Active Pharmaceutical Ingredient from an unapproved source.

Terminated Unapproved drug KVK-Tech, Inc. NDC 10702-010-01 D-1030-2014

Recalls by year